{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:43:34Z","timestamp":1782913414817,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Pathogenesis and Therapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.cpt.2024.05.003","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T06:56:46Z","timestamp":1717138606000},"page":"129-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk of autoimmunity, cancer seeding, and adverse events in human trials of whole-tissue autologous therapeutic vaccines"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-1446","authenticated-orcid":false,"given":"Garrett","family":"Gianneschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Scolpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Oleske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpt.2024.05.003_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034714","article-title":"Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews","volume":"10","author":"Khan","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.cpt.2024.05.003_bib2","first-page":"638","article-title":"Experiments on immunotherapy of warts and condylomas","volume":"4","author":"Biberstein","year":"1925","journal-title":"Clinical Weekly"},{"key":"10.1016\/j.cpt.2024.05.003_bib3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00262-009-0784-6","article-title":"Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting","volume":"59","author":"May","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.cpt.2024.05.003_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/11795549221110501","article-title":"Pilot study of combination Gemogenovatucel-T (Vigil) and durvalumab in women with relapsed BRCA-wt triple-negative breast or ovarian cancer","volume":"16","author":"Barve","year":"2022","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.cpt.2024.05.003_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41417-021-00317-5","article-title":"Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer","volume":"29","author":"Rocconi","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.cpt.2024.05.003_bib6","first-page":"2359","article-title":"Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study","volume":"5","author":"Sobol","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpt.2024.05.003_bib7","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.1990.8.11.1858","article-title":"Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients","volume":"8","author":"Berd","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpt.2024.05.003_bib8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.1133427","article-title":"The consensus coding sequences of human breast and colorectal cancers","volume":"314","author":"Sj\u00f6blom","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.cpt.2024.05.003_bib9","series-title":"Common terminology criteria for adverse events (CTCAE) version 5.0","first-page":"1","year":"2017"},{"key":"10.1016\/j.cpt.2024.05.003_bib10","series-title":"Phase II study of immunotherapy with autogenous papilloma vaccine in patients with recurrent juvenile papilloma of the larynx. NCT00002454","author":"Oleske","year":"1999"},{"key":"10.1016\/j.cpt.2024.05.003_bib11","first-page":"417","article-title":"Juvenile papilloma of the larynx","volume":"121","author":"Oleske","year":"1971","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.cpt.2024.05.003_bib12","first-page":"1","article-title":"Autogenous vaccine in cancer patients","volume":"114","author":"Graham","year":"1962","journal-title":"Surg Gynecol Obstet"},{"key":"10.1016\/j.cpt.2024.05.003_bib13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(98)07186-4","article-title":"Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial","volume":"353","author":"Vermorken","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cpt.2024.05.003_bib14","doi-asserted-by":"crossref","DOI":"10.3171\/foc.2000.9.6.10","article-title":"Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes","volume":"9","author":"Sloan","year":"2000","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.cpt.2024.05.003_bib15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/BF01741726","article-title":"Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells","volume":"32","author":"McCune","year":"1990","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.cpt.2024.05.003_bib16","first-page":"62","article-title":"Autogenous vaccine therapy for condyloma acuminatum. A double-blind controlled study","volume":"58","author":"Malison","year":"1982","journal-title":"Br J Vener Dis"},{"key":"10.1016\/j.cpt.2024.05.003_bib17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF03023479","article-title":"Study on solidified tumor vaccine prepared from autogenous cancerous tissue","volume":"7","author":"Huang","year":"1995","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.cpt.2024.05.003_bib18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00007611-197002000-00017","article-title":"Treatment of condyloma acuminata by autogenous vaccine","volume":"63","author":"Powell","year":"1970","journal-title":"South Med J"},{"key":"10.1016\/j.cpt.2024.05.003_bib19","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1089\/104303402760293556","article-title":"Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I\/IB study","volume":"13","author":"Mahvi","year":"2002","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.cpt.2024.05.003_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1001\/archderm.1944.01510130015005","article-title":"Immunization therapy of warts","volume":"50","author":"Biberstein","year":"1944","journal-title":"Arch Dermatol Syphilol"},{"key":"10.1016\/j.cpt.2024.05.003_bib21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/archderm.1934.01460130052009","article-title":"Autolysate therapy for verruca vulgaris","volume":"30","author":"Cormia","year":"1934","journal-title":"Arch Dermatol Syphilol"},{"key":"10.1016\/j.cpt.2024.05.003_bib22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/sj.cgt.7700922","article-title":"Phase 1\/2 trial of autologous tumor mixed with an allogeneic GVAX\u00ae vaccine in advanced-stage non-small-cell lung cancer","volume":"13","author":"Nemunaitis","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.cpt.2024.05.003_bib23","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1288\/00005537-196706000-00011","article-title":"Evaluation of an autogenous laryngeal papilloma vaccine","volume":"77","author":"Shipkowitz","year":"1967","journal-title":"Laryngoscope"},{"key":"10.1016\/j.cpt.2024.05.003_bib24","doi-asserted-by":"crossref","DOI":"10.2217\/cns-2018-0009","article-title":"Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts","volume":"7","author":"Bota","year":"2018","journal-title":"CNS Oncol"},{"key":"10.1016\/j.cpt.2024.05.003_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijpam.2015.05.004","article-title":"BCG related complications: a single center, prospective observational study","volume":"2","author":"Alfawaz","year":"2015","journal-title":"Int J Pediatr Adolesc Med"},{"key":"10.1016\/j.cpt.2024.05.003_bib26","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11882-004-0010-8","article-title":"Update on side effects from common vaccines","volume":"4","author":"Song","year":"2004","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.cpt.2024.05.003_bib27","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/1097-0142(196911)24:5<932::AID-CNCR2820240510>3.0.CO;2-5","article-title":"Treatment of advanced cancer with active immunization","volume":"24","author":"Cunningham","year":"1969","journal-title":"Cancer"},{"key":"10.1016\/j.cpt.2024.05.003_bib28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1349-7006.2002.tb01265.x","article-title":"Autologous fixed tumor vaccine: a formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma","volume":"93","author":"Peng","year":"2002","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.cpt.2024.05.003_bib29","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3748\/wjg.v11.i5.700","article-title":"Tumor vaccine against recurrence of hepatocellular carcinoma","volume":"11","author":"Peng","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cpt.2024.05.003_bib30","first-page":"409","article-title":"Autologous tumor vaccine lowering postsurgical recurrent rate of hepatocellular carcinoma","volume":"53","author":"Peng","year":"2006","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/j.cpt.2024.05.003_bib31","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/j.1349-7006.2007.00518.x","article-title":"Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients","volume":"98","author":"Ishikawa","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cpt.2024.05.003_bib32","first-page":"1537","article-title":"Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer","volume":"57","author":"Simons","year":"1997","journal-title":"Cancer Res"}],"container-title":["Cancer Pathogenesis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713224000326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713224000326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T12:03:26Z","timestamp":1741867406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949713224000326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2949713224000326"],"URL":"https:\/\/doi.org\/10.1016\/j.cpt.2024.05.003","relation":{},"ISSN":["2949-7132"],"issn-type":[{"value":"2949-7132","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of autoimmunity, cancer seeding, and adverse events in human trials of whole-tissue autologous therapeutic vaccines","name":"articletitle","label":"Article Title"},{"value":"Cancer Pathogenesis and Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpt.2024.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of Chinese Medical Association (CMA).","name":"copyright","label":"Copyright"}]}}